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Antibiotic development is frequently plagued by the rapid emer-
gence of drug resistance. However, assessing the risk of resistance
development in the preclinical stage is difficult. Standard labora-
tory evolution approaches explore only a small fraction of the
sequence space and fail to identify exceedingly rare resistance
mutations and combinations thereof. Therefore, new rapid and
exhaustive methods are needed to accurately assess the potential
of resistance evolution and uncover the underlying mutational
mechanisms. Here, we introduce directed evolution with random
genomic mutations (DIvERGE), a method that allows an up to
million-fold increase in mutation rate along the full lengths of
multiple predefined loci in a range of bacterial species. In a single
day, DIvERGE generated specific mutation combinations, yielding
clinically significant resistance against trimethoprim and ciproflox-
acin. Many of these mutations have remained previously unde-
tected or provide resistance in a species-specific manner. These
results indicate pathogen-specific resistance mechanisms and the
necessity of future narrow-spectrum antibacterial treatments. In
contrast to prior claims, we detected the rapid emergence of re-
sistance against gepotidacin, a novel antibiotic currently in clinical
trials. Based on these properties, DIvERGE could be applicable to
identify less resistance-prone antibiotics at an early stage of drug
development. Finally, we discuss potential future applications of
DIvERGE in synthetic and evolutionary biology.
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The emergence of drug resistance against existing antimicrobials iscurrently responsible for 700,000 worldwide deaths annually (1).
However, many pharmaceutical companies have discontinued their
antibiotic research programs. This is partly due to the rapid spread of
multidrug-resistant bacteria, which makes the commercial success of
new antimicrobial drugs unpredictable (2). Meanwhile, serious
infection-causing Gram-negative bacteria are becoming resistant
to all previously effective antibiotics on the market. The case of
GSK2251052—a novel compound developed by GlaxoSmithKline
(GSK)—highlights these problems. GSK2251052 inhibits bacterial
leucyl-tRNA synthetase and possesses many beneficial properties
of an antibiotic for treating human infections by Gram-negative
pathogens. However, resistance against GSK2251052 by genomic
mutations was identified in animal models and in patients during
a phase 2b trial (3). As a consequence, GSK has discontinued
clinical development of GSK2251052 (4).
In general, resistance can be mediated by chromosomal gene-
resistance mutations or by broad host-range plasmids. The relative
importance of these genetic mechanisms in resistance evolution
depends on the antibiotic and the bacterial pathogens considered
(5). For example, clinically significant levels of resistance against
DNA gyrase and topoisomerase IV inhibitors are generally enco-
ded by multiple resistance mutations in the pathogen genome.
Resistance genes encoded by plasmids provide a much lower level
of resistance against these antibiotics. Accordingly, this work studies
chromosomal gene-resistance mutations with a focus on trimetho-
prim and DNA gyrase inhibitors.
In the early phase of drug development, researchers typically
identify numerous lead molecules with antimicrobial activities. It is
imperative to estimate the rate of resistance evolution at this early
stage of development (3, 6). However, this is a complex problem
for three main reasons: (i) the large diversity of molecular mech-
anisms contributing to resistance, (ii) the numerous pathogenic
bacteria to be considered, and (iii) the large number of potential
candidate molecules to be tested. Unfortunately, standard microbial
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protocols are slow, have a low coverage, and may fail to predict the
frequency and molecular mechanisms of antibiotic resistance by
genomic mutations (3, 7, 8). The two most widespread methods,
fluctuation tests and serial passage experiments, generally rely on
spontaneous mutational processes and therefore can explore only a
small fraction of the sequence space (6, 9). This is especially
problematic if a high level of resistance demands the simultaneous
acquisition of multiple, rare mutations, many of which seemingly
provide little benefit individually (10–12).
Recent genome-engineering technologies enable targeted
mutagenesis of predefined DNA segments and therefore are
promising alternative tools to explore resistance mutations in a
systematic manner. However, current methods suffer from several
limitations. The length of the targeted regions is generally limited
(13–16), precise adjustment of the mutation rate is unsolved (13–
15), or the mutational spectrum is highly biased (13–15, 17).
Furthermore, throughput is often moderate due to constraints on
maximum library size (18) and the maximum number of targeted
regions (17, 19, 20). For a more detailed comparison of existing in
vivo mutagenesis protocols, see Dataset S1. Limitations also hold
for multicopy plasmid-based mutagenesis platforms, including
error-prone PCR, as they distort native expression levels and fail
to identify recessive mutations (21–25).
Multiplex automated genome engineering (MAGE) and related
methods have been proposed to mutagenize the full length of in-
dividual genes (26–30). Existing approaches demand a large number
of individual oligos even for targets of modest size, and therefore
targeted mutagenesis of long genomic regions is tedious (Dataset
S1). Here, we present directed evolution with random genomic
mutations (DIvERGE), a method that addresses the aforemen-
tioned shortcomings of current in vivo mutagenesis techniques.
DIvERGE enables mutagenesis of predefined long genomic regions
(Fig. 1). Moreover, it (i) has broad, controllable mutagenesis spectra
for each nucleotide position, (ii) allows very high mutation rates of
the target sequences, (iii) enables multiple rounds of mutagenesis
and selection, (iv) is applicable to a range of host species without the
need for prior genomic modification, and is also (v) cost-effective.
We show that this method is particularly well-suited to screen
the resistance profiles of antibiotic compounds. Specifically, in a
single day DIvERGE generated clinically significant resistance
against trimethoprim and ciprofloxacin in multiple bacterial
species. It also allowed us to predict the rise of high level of
resistance (and the underlying mutational combinations) against
gepotidacin, a novel antibiotic currently in clinical trials.
Results
Overview of DIvERGE.DIvERGE is based on a unique single-strand
(ss) DNA oligonucleotide (oligo) design strategy where long,
continuous genomic segments are covered by the alignment of
partially overlapping mutagenized DNA oligos (Fig. 1). Tuning of
the nucleotide composition in each synthetic DNA oligo ensures
that each possible mutation is represented in the synthesized oligo
pool. These oligo pools are synthesized using a soft-randomization
protocol (31). In a nutshell, soft-randomization introduces a small
amount of nucleotide mixture at specific variable positions of the
wild-type sequence. It thereby generates oligos with randomly
positioned mutations. Moreover, soft-randomization enables the
precise control of the rate and spectrum of mutations in the tar-
geted segment (SI Appendix, Fig. S1).
The randomized oligos fully cover the locus of interest and in-
duce mutagenesis at their target after incorporation. Indeed, prior
works indicate that limiting the number of mismatches compared
with the target sequence allows for an efficient genomic in-
tegration of DNA oligos (26, 32, 33) (SI Appendix, Fig. S2), while
the overlapping design permits random and uniformly distributed
mutagenesis along exceptionally long DNA segments. We note
that application of soft-randomized oligos circumvents the need
for cost-demanding, massively parallel oligonucleotide synthesis.
Similarly to prior approaches (26, 28), DIvERGE (Fig. 1)
proceeds via cell growth (1), oligo delivery and incorporation (2),
mutagenesis (3), leading to a highly elevated genetic diversity of
the mutagenized population (4). In the following, we step-by-
step demonstrate the potentials of the method and apply it to
study antibiotic resistance.
Uniform and Adjustable Mutagenesis of Selected Genomic Targets.
We first tested whether a single randomized oligo pool can keep
the mutation rate and mutational spectrum uniform along its
sequence. To this end, 90-nt-long DNA oligos, complementary
to a landing pad sequence, previously integrated into the genome
of Escherichia coli K-12 MG1655 (34), were synthesized in a way
that each nucleotide position was spiked with up to 20% of all
three possible mismatching nucleotides. Spiking ratio is defined
as the fraction of the mismatching nucleotides during oligo
synthesis. For the estimated distribution of mutation numbers at
each spiking ratio, see SI Appendix, Table S1.
The nucleotide composition within the oligo pool was con-
firmed using Illumina high-throughput (HT) sequencing. Re-
assuringly, we achieved balanced mutational distribution across
the entire length of the oligo (Fig. 2A). Moreover, the number of
mutations within each oligo was precisely adjustable depending
on the level of spiking (SI Appendix, Fig. S1 and Table S1).
Next, we examined the incorporation of these ssDNA oligo pools
into the bacterial genome at the landing pad sequence. Iterative
recombineering was performed utilizing pORTMAGE, an approach
capable of achieving highly efficient allelic replacement without off-
target effects (34). Using randomized oligos, we targeted two 90-bp-
long regions within the landing pad and performed five DIvERGE
cycles with each. The mutation frequency was then determined us-
ing HT sequencing of the targeted landing pad sequence, revealing
that mutagenesis was extended to 87% of the length of the entire
oligos (Fig. 2B). Consistent with prior works that characterized
oligo incorporation in E. coli (33, 35, 36), we noted a sharp drop in
mutation frequency at each oligo terminus (Fig. 2B).
Fig. 1. Overview of DIvERGE mutagenesis. Randomized DNA oligo synthesis
precisely controls the rate of mutations in partially overlapping oligos. These
oligos fully cover the locus of interest and induce mutagenesis at their target
after incorporation. Similarly to prior approaches (26, 28), DIvERGE proceeds via
cell growth (1), oligo delivery and incorporation (2), andmutagenesis (3), leading
to a highly elevated genetic diversity of the mutagenized population (4).
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Intermediate (2%) spiking ratios produced the highest muta-
tion frequency at the target sequence. The average number of
mutations within the target sequence increased with the spiking
ratio (Fig. 2C). However, oligos with low similarities to their
target sequence have a reduced capacity to integrate into the
genome (26, 32) (SI Appendix, Fig. S2). Therefore, oligo pools
with numerous mismatches may actually limit the efficiency of
mutagenesis of the target sequence. Indeed, we observed a sharp
decrease in the incorporation efficiency of oligo pools with a
spiking ratio above 5% (Fig. 2D).
Reassuringly, no major bias in the mutational spectrum was
detected along the target region: all individual mutation categories
fell between 13.8% and 22.4% in the genomic pool (Table 1). This
is a significant advantage over typical in vitro mutagenesis meth-
ods [such as error-prone PCR (37–39)], which tend to display
significant mutational bias. Moreover, the extent of sequence di-
versity of the population was tunable by the number of DIvERGE
cycles and the spiking ratio of the oligo pool (Fig. 2E).
Performing five DIvERGE cycles with medium-level randomization
(i.e., 2% spiking ratio within the synthetic oligo sequence) resulted in
an over 106-fold increase in mutation rate at the target region
compared with the background level. This corresponds to an in-
crease from 2.2 × 10−10 to 2.4 × 10−4 mutations per nucleotide per
generation (SI Appendix, Table S6), as measured using HT se-
quencing of the landing pad sequence. Importantly, the mutation
rate of nontargeted regions—measured at the intermediate region
of the landing pad between the two target sequences—remained low
(Fig. 2B). Overall, DIvERGE allowed efficient control of sequence
diversification at a chosen target site by oligo randomization.
DIvERGE Can Mutagenize Extended Genomic Regions. Next, we aimed
to extend the genomic target region undergoing mutagenesis by
designing and synthesizing multiple, overlapping, and randomized
oligos that cover an entire gene and its promoter region. As a
target, we chose the essential gene folA, encoding dihydrofolate
reductase (FolA) and its promoter region. The selection of folA
has clinical relevance, as dihydrofolate reductase is the target of
the widely used antimicrobial drug trimethoprim (40). Prior
studies demonstrated that under prolonged trimethoprim pres-
sure, the evolution of resistance proceeds predominantly through
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Fig. 2. DIvERGE mutagenizes selected genomic targets. (A) Mutation frequency along a randomized 90-mer oligonucleotide. A 0.5% nucleoside-
phosphoramidite spiking ratio was used to mutate each nucleotide position along the entire length of the sequence. (B) Genomic mutation frequency, mea-
sured as the background-normalized frequency of mutations at a given position, with DIvERGE in E. coli K-12 MG1655 after five cycles of mutagenesis. Two 90-bp
genomic regions separated by an intermediate 70-bp region were targeted for mutagenesis (indicated as black lines beneath the x axis). A cut-off of 0.2% (dashed
line) was used as a threshold to qualify diversified positions, all values below indicate detection limits of the employed sequencing technology (SI Appendix, SI
Materials and Methods). (C) The frequency of SNP events per site, introduced by DIvERGE mutagenesis, as a function of the DNA-synthesis spiking ratio. Samples
represent allelic composition after five mutagenesis cycles with the corresponding spiking ratio, while control represents mutagenesis with a nonspiked oligo. (D)
Incorporation efficiencies of randomized oligos with increasing levels of the DNA-synthesis spiking ratio during DIvERGE in E. coli K-12 MG1655. Ten percent and
20% spiked oligo incorporations were below the detection threshold of 0.01 and therefore not visible on the graph. (E) Mutation frequency at the target site in
consecutive DIvERGE cycles in E. coli K-12 MG1655. Oligo soft-randomization was applied at two spiking ratios (0.5% and 2%, respectively). Mutation frequency
indicates background-normalized mutation frequency at a given position. Error bars represent SE based on diversified positions (n = 154).
Table 1. Mutagenic spectrum of DIvERGE
Mutational bias indicator
Oligonucleotide Genomic
Frequency SD Frequency SD
Transitions/Transversions
(Ts/Tv)
0.6 0.1 0.6 0.1
A → G, T → C (%) 13.8 0.8 13.8 0.4
G → A, C → T (%) 22.4 1.5 22.2 1.8
A → T, T → A (%) 15 1.1 17.1 1.4
A → C, T → G (%) 12.9 0.5 13.8 0.2
G → C, C → G (%) 14.2 0.4 14.8 1.1
G → T, C → A (%) 21.7 0.2 18.2 0.6
Spectrum of mutations in a randomized oligo after 0.5% spiked DNA
synthesis (TETRM1_05) and the resulting spectrum of mutations at the ge-
nomic target after five DIvERGE cycles in E. coli K-12 MG1655. Frequencies
and SD values were calculated from sequencing data.
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mutations in folA (41, 42); therefore, mutagenesis of this gene
produces an easily detectable phenotype. Because resistance-
conferring mutations have been detected both in the regulatory
(43) and in the protein-coding regions of folA (22) (Dataset S2),
we diversified both regions in E. coli K-12 MG1655. To this aim,
we used eight overlapping mutagenized oligos to cover folA (SI
Appendix, SI Materials and Methods). Based on the observed in-
corporation pattern of mutations from individual oligos (Fig. 2B),
9-nt-long overlaps were designed between neighboring oligos to en-
sure an equally high probability of mutagenesis at all positions.
Overall, one oligo targeted the 81-bp-long promoter region, while
seven targeted the 480-bp-long protein-coding sequence (Dataset S3).
We generated folA variant libraries with single-point muta-
tions in the target sequence. Single rounds of DIvERGE muta-
genesis cycles were carried out separately with each of the eight
oligos. The resulting mutants were then subjected to mild tri-
methoprim selection pressure and the genotypes of resistant
clones were determined by sequencing (SI Appendix, SI Materials
and Methods). Clones with more than one mutation were ex-
cluded from further analysis, thus focusing on the adaptive
single-step mutational landscape (SI Appendix, Table S2 and
Dataset S4). We found that 81% of the identified single-point
mutations reside in the protein-coding region, primarily localized
in the active site cavity and the NADPH binding site of dihy-
drofolate reductase (44), while the rest were in the promoter
region. DIvERGE detected 17 previously described (22, 41–43,
45) mutations against trimethoprim, many of which have been
found clinical isolates (Dataset S2), and unveiled seven novel ones.
Analysis of a subset of these mutations individually confirmed their
resistance-conferring phenotypes (SI Appendix, Fig. S4 and Table
S2). These results are all of the more remarkable, as a single round
of DIvERGE mutagenesis takes only ∼5 h to perform.
DIvERGE Promotes Exceptionally Rapid Evolution of High-Level
Antibiotic Resistance. Because high-level trimethoprim resistance
generally demands multiple mutations in folA, we next subjected
E. coli K-12 MG1655 to multiple rounds of DIvERGE muta-
genesis. Five consecutive mutagenesis cycles were carried out, si-
multaneously targeting all nucleotide positions in the regulatory
and protein-coding regions.
Iterative integration of the oligos resulted in randomization of
the targeted regions (Fig. 3A, SI Appendix, Table S3, and Dataset
S4) and successful generation of higher-order mutational com-
binations (Fig. 3B and Dataset S5). After only five DIvERGE
cycles completed in a single day, we identified folA mutants with
up to an 895-fold increase in trimethoprim resistance compared
with that of the wild type (Table 2). Resistance was quantified by
IC75, the trimethoprim concentration that inhibits growth by
75% compared with the drug-free condition.
With the multiround directed evolution of folA, higher-level
mutational combinations were generated at high efficiency.
Some of these variants displayed a more than 3,900-fold increase
in their trimethoprim-resistance level compared with wild-type
E. coli K-12 MG1655 (Table 3 and SI Appendix, Fig. S4).
One may argue that the oligo set designed to target the wild-type
folA may revert mutations that had accumulated at an earlier stage
of laboratory evolution. To address this issue, we focused on a
previously identified folA variant selected using mild trimethoprim
stress with three mutations in E. coli K-12 MG1655. We carried out
an additional five DIvERGE cycles on this mutant variant and se-
quenced the resulting library. Reassuringly, no substantial decrease
in the level of nucleotide variation was observed in the folA variant,
with the only exception being the nucleotides directly adjacent to the
three preexisting mutations (SI Appendix, Fig. S3 and Datasets S4 and
S7). Overall, DIvERGE generated a diverse set of trimethoprim-
resistant variants, simultaneously retaining the three mutations
introduced before the mutagenesis-selection cycles.
This indicates that there is no need for new oligo design and
synthesis after each round of mutagenesis. Therefore, the mu-
tagenesis cycles are rapid, uninterrupted, and can be potentially
scaled up toward many parallel populations.
DIvERGE Minimizes Off-Target Effects.We next assessed the potential
off-target mutagenesis of DIvERGE. The extent of off-target
mutagenesis is particularly important because the accumulation of
undesired, off-target mutations could interfere with the phenotypic
effects of the engineered modifications. To quantify off-target
mutagenesis, we measured the fraction of rifampicin-resistant cells
in DIvERGE treated populations while simultaneously mutage-
nizing folA. Importantly, the corresponding resistance-conferring
locus (rpoB) was not targeted by DIvERGE.
DIvERGE-treated populations showed no significant increase in
the frequency of rifampicin-resistant cells after five cycles of muta-
genesis compared with that of untreated wild-type populations (Fig.
4A). This confirms earlier results on the shortage of mutations in
nontargeted regions of the landing pad sequence (Fig. 2B). Fur-
thermore, no significant fitness decline was observed in DIvERGE-
derived trimethoprim resistant clones (Fig. 4B), indicating a short-
age of fitness-decreasing off-target mutations. Taking these data
together, we find that DIvERGE selectively and efficiently targets
predefined genomic loci, while minimizing off-target effects.
DIvERGE Is Applicable to Multiple Bacterial Species. We next tested
whether DIvERGE could be applicable to the mutagenesis of
distant relatives of E. coli as well. We selected as models Salmo-
nella enterica and the opportunistic pathogen Citrobacter freundii,
all of which diverged from E. coli ∼100–200 million y ago (34).
To characterize the efficiency of mutagenesis with DIvERGE in
a uniform manner across species, we integrated the same landing-
pad sequence utilized for E. coli into the genomes of these bacterial
species (34). We thereby characterized the incorporation of the
oligos using the same oligo set and the same protocol as in E. coli
(SI Appendix, SI Materials and Methods). Akin to what we observed
in E. coli, the randomized oligos efficiently induced mutagenesis in
both S. enterica and C. freundii (Fig. 5 A and B and SI Appendix,
Fig. S5 and Table S4). Consistent with results in E. coli (Fig. 2C),
the highest mutation frequency was achieved using oligos with 2%
spiking ratios. As expected, mutation frequency correlated with the
number of DIvERGE mutagenesis cycles (SI Appendix, Fig. S5).
Overall, we achieved at least a 105-fold increase in mutation rate at
the target sequence in both species (SI Appendix, Table S4).
Differences in Mutational Effects Between Closely Related Pathogens.
We targeted folA and its promoter sequence in S. enterica and
another clinically relevant strain, uropathogenic E. coli CFT073
(UPEC). Trimethoprim is frequently deployed against these
pathogens in the clinic (46). The protocols employed were similar
A B
Fig. 3. DIvERGE mutagenesis along the full length of an antibiotic re-
sistance gene. (A) Mutation frequency at the E. coli K-12 MG1655 folA locus
after five cycles of DIvERGE mutagenesis. Positions 0 and 480 refer to the
start and end of the protein-coding sequence of folA. Mutation frequency is
defined as the background-normalized frequency of substitutions occurring
at a given position. (B) Naïve library composition after five cycles of DIvERGE
mutagenesis of the E. coli K-12 folA locus. The frequency of sequencing
reads with the given number of SNPs within the target sequence.
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to that for E. coli K-12 MG1655. Species and strain-specific oligos
were synthesized, resulting in eight overlapping oligos for each
pathogen. A single round of DIvERGE generated folA variant
libraries with single-point mutations in the target sequence. As for
E. coliK-12 MG1655, ∼3,000 resistant clones were selected at mild
trimethoprim dosage and were subsequently sequenced. Com-
parison of the adaptive mutations in E. coli K-12, E. coli CFT073,
and S. enterica revealed novel resistance mutations (SI Appendix,
Fig. S6 and Table S2 and Dataset S4). Despite the 99% sequence
similarity of folA between E. coli K-12 and E. coli CFT073, the
conferred relative resistance level by the same mutation frequently
differed between the two strains (SI Appendix, Table S2). Most
notably, the Ala7Ser mutation in the protein-coding region pro-
vided resistance in E. coli CFT073 only (Fig. 5C).
We next compared the mutational profiles of S. enterica and
E. coli CFT073 using five rounds of DIvERGE. This resulted in the
rapid generation of combinatorial folA mutants with trimethoprim
resistance levels up to 3,873-times higher than that of the corre-
sponding wild-type strains (SI Appendix, Table S5). It is worth noting
that the corresponding trimethoprim dosages are comparable with
the dosage regularly employed to treat urinary tract infections (46).
Sequence analysis of 1,000 resistant clones from each organism
confirmed that high levels of resistance frequently required mul-
tiple mutations within the regulatory and protein-coding regions of
folA (SI Appendix, Table S5 and Dataset S6). However, differences
in mutational hot-spots were detected between the two species
(Fig. 5D and SI Appendix, Fig. S6 and Table S5). Notably, a pro-
moter position (C-61) and a C-terminal amino acid coding position
(Phe-153) were mutated predominantly in S. enterica (Fig. 5D).
Mutations at Phe-153 may act as compensatory mutations partially
restoring catalysis, paired with active site mutations that lower cat-
alytic activity (47, 48). In line with prior studies with E. coli (22, 42,
45), high levels of trimethoprim resistance mostly evolved via com-
binations of mutations in the promoter and the protein’s active site.
Taken together, these results indicate differences in muta-
tional effects across related species.
DIvERGE Discovers Antibiotic Resistance Mutations Against a
Fluoroquinolone. Next, we addressed the question whether DIvERGE
can mutagenize longer genomic regions with a comparable reso-
lution. To this end, we mutagenized the gyrA locus in E. coli K-12
MG1655. GyrA encodes the A subunit of DNA gyrase, which is
targeted by fluoroquinolones (49). GyrA is nearly five-times longer
than folA mutagenized in the previous section.
We investigated resistance hot-spots toward ciprofloxacin, one
of the most frequently used fluoroquinolones (49). After per-
forming DIvERGE mutagenesis with 38 overlapping oligos cov-
ering the entire promoter and protein-coding regions, we selected
1,000 resistant mutants under mild ciprofloxacin stress [i.e., five-
fold above the wild-type minimum inhibitory concentration
(MIC)]. Sequence analysis revealed that all putative resistance
mutations reside solely in the protein-coding region. Clinically
occurring mutations at Ser-83 and Asp-87 and their combinations
dominated the observed mutational landscape (10, 50–52). Re-
markably, three frequently observed individual mutations at posi-
tions 288, 334, and 785 fall outside of the well-described quinolone
resistance determining region of gyrA (51) (Dataset S6). To the
best of our knowledge, this link of these positions to quinolone
resistance in E. coli is unique. Reconstruction of the corresponding
GyrA Gly288Asp (G288D) allele in a wild-type genetic back-
ground confirmed its resistant phenotype (Fig. 5E).
Future studies are needed to determine whether these positions
are clinically relevant. There could be two reasons why this par-
ticular mutation has remained undetected so far. First, the level of
ciprofloxacin resistance provided by G288D is relatively modest
(Fig. 5E). Second, G288D may induce a fitness cost in the absence
of antibiotic. To investigate the second possibility, we introduced
G288D and two clinically known mutations (S83L, D87N) into
wild-type E. coli, and measured the growth rates of the corre-
sponding mutants in vitro (Fig. 5F). We found that G288D reduces
growth rate by 8.3% compared with the wild type, while S83L and
D87N have no detectable effects on fitness. These results indicate
that future work should study resistance level and potential fitness
costs of mutants simultaneously and in a HT manner.
Mutagenesis Along the Full Lengths of Multiple Genes. Based on the
results of the previous section, we sought to chart other putative
resistance determinants along multiple target genes of cipro-
floxacin. In Gram-negative bacteria (such as E. coli), cipro-
floxacin’s primary drug target is the DNA gyrase complex (50).
However, ciprofloxacin also has a lower binding affinity to the
homologous DNA topoisomerase IV complex (53) as well. GyrA
Table 2. Trimethoprim susceptibility of individually selected E. coli K-12 MG1655 folA mutants
Strain ID
FolA regulatory
mutation FolA mutation
Trimethoprim
IC75 (μg/mL)
IC75 (fold-change compared
with wild type)
Escherichia coli K-12#1 C-58T A26T, L28R, P39R 1,254 895.7
Escherichia coli K-12#2 C-58T, T-74A P21P, L28R, N147D 447.5 319.6
Escherichia coli K-12#3 C-58T L28R 610 492.8
Escherichia coli K-12#4 C-43T, C-58T A26D, L28R, H45R 794 567.1
IC75 (Trimethoprim) of the wild type equals 1.4 μg/mL. Data represent IC75 based on the average of three independent
measurements.
Table 3. Trimethoprim susceptibility of individually selected E. coli K-12 MG1655 folA mutants after two rounds
of consecutive mutagenesis-selection cycles
Strain ID FolA regulatory mutation
FolA mutation
(or same-sense DNA mutation)
IC75 (fold-change compared
with wild type)
Escherichia coli K-12#8 C-58A A26S, L28R, W30C, (C132G) >3,900
Escherichia coli K-12#11 C-58A A26T, L28R, W30C >3,900
Escherichia coli K-12#12 C-58A A26T, L28R, (C132G), M88L 2,140
Escherichia coli K-12#23 C-58A A26T, L28R, (C132G) 1,430
IC75 (trimethoprim) of the multiround DIvERGE generated folA variants in E. coli K-12 MG1655, with new mutation-combinations
emerging compared with the parental variant (containing C-58A, W30C, and C132G, a same-sense mutation). Data represent IC75 based
on the average of three independent measurements.
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and GyrB constitute the gyrase complex, while ParC and ParE
are involved in the topoisomerase IV complex.
To identify mutations that promote resistance, we mutagenized all
four constituents along the full lengths of their corresponding protein-
coding DNA regions. Accordingly, we performed a single round of
DIvERGE mutagenesis in E. coli K-12 MG1655, using 130 oligos
covering 9,503 base pairs (Dataset S3). The resulting mutants were
then subjected to mild ciprofloxacin stress (i.e., at a dosage twofold
higher than the wild-type MIC), and the genotypes of 3,000 resistant
clones were determined (SI Appendix, SI Materials and Methods).
Sequence analysis indicated mutagenesis at multiple target loci
and, as expected, the overwhelming majority of the identified al-
leles carried single mutations only (Fig. 6A and Dataset S6).
Mutations were detected in gyrA and gyrB, but not in parC and
parE (Fig. 6A). Most notably, the analysis revealed a 46-aa-long
region of the GyrB protein mutated in 22.4% of the analyzed
alleles (Dataset S6). Protein structure studies demonstrated that
this protein region is in close proximity of GyrA (54, 55) in the
gyrase complex and may interact with fluoroquinolones (Fig. 6B).
Moreover, we note that the shortage of resistance-conferring
mutations in ParC and ParE is in-line with prior observations (50).
Mutations accounting for the first step of fluoroquinolone re-
sistance development are generally in the primary drug target, and
mutational effects in ParC and ParE rely heavily on specific epi-
static interactions with mutations in GyrA (56). In a future work,
DIvERGE can investigate the coevolution of the two protein
complexes by performing repeated mutagenesis selection.
Predicting Resistance Against an Antibiotic Currently Under Clinical
Trial. Based on the above results, we anticipated that DIvERGE
could forecast long-term clinical efficacy of multiple antibiotic
candidates at an early stage of development. As the first step in this
direction, we focused on gepotidacin (GSK2140944). Gepotidacin
is an antibiotic candidate currently in clinical phase 2 trials. It se-
lectively inhibits bacterial DNA gyrase and topoisomerase IV by an
entirely novel mode-of-action, not observed in any other currently
approved antibiotic (57). A recent study failed to recover resistant
clones in Neisseria gonorrhoeae (58), but this result may reflect
limitations of standard microbial assays for detection of high levels
of resistance.
To investigate this problem in more detail, we first attempted
to generate resistance mutants by exposing as many as 1010 wild-
type E. coli cells to gepotidacin stress in a standard frequency of
resistance assay (59). No resistant variants emerged after 72 h. In
contrast, we subjected four potential target genes (gyrA, gyrB,
parE, and parC) to a single round of DIvERGE mutagenesis.
DIvERGE generated E. coli mutants displaying a 557-fold in-
crease in resistance level compared with the corresponding wild
type (Fig. 6C). Sequence analysis of three independently isolated
clones indicated that a combination of two specific mutations is
sufficient to reach such high levels of resistance. In particular, the
subsequent introduction of the identified GyrA Asp82Asn and
ParC Asp79Asn mutations into the genomes of E. coli CFT073
(UPEC), C. freundii ATCC 8090, and Klebsiella pneumoniae
ATCC 10031 revealed that they greatly increase gepotidacin re-
sistance levels in pathogenic strains as well (Table 4).
The above analyses indicate the utility of DIvERGE to explore
rare combinations of resistance mutations. We anticipate that it
will be a useful tool for rapid resistance-mutation screening of
novel antimicrobial compounds at an early stage of drug devel-
opment with the aim to identify candidate molecules that are less
prone to resistance.
Discussion
In summary, DIvERGE offers a versatile solution for high-
precision directed evolution: it allows directed mutagenesis along
the full lengths of multiple loci in their native genomic context
in multiple bacterial species. The properties of DIvERGE are as
follows (Fig. 1).
First, and most importantly, DIvERGE can mutagenize the full
lengths of multiple protein-coding genes (Fig. 6A). No constraint
is placed on the target sequence by the availability of a proto-
spacer adjacent motif, a strict requirement for CRISPR/Cas9-
based mutagenesis techniques (13–15, 18). Second, DIvERGE
allows the unbiased introduction of mutations at each targeted
nucleotide position (Table 1). This is an advantage over tech-
niques where mutational spectra are biased or limited to certain
positions (13–15, 27, 29, 30). Third, the rate of mutagenesis can also
be precisely adjusted (Fig. 2 C and E) and in certain cases can
achieve an up to 106-fold increase compared with basal levels. This
range exceeds that of several other in vivo methods (60). Fourth,
DIvERGE can be performed iteratively using the same oligo pools,
permitting multiple rounds of mutagenesis and selection. Fifth, as
DIvERGE utilizes the pORTMAGE plasmids (34), it is applica-
ble to multiple clinically relevant enterobacterial species. Sixth, as
DIvERGE does not involve permanent inactivation of the en-
dogenous mismatch-repair system (34), the targeted mutagenesis
is coupled with the minimization of unwanted off-target mutations
(Figs. 2B and 4A). Finally, DIvERGE is cost-effective, as it does
not require a large set of predesigned oligos. It relies on a single
set of soft-randomized oligos that can easily be manufactured at
a modest cost.
In this work, we used DIvERGE to study antibiotic resistance.
Standard microbial protocols, such as fluctuation tests and serial
passage experiments, generally rely on spontaneous mutational
processes. Therefore, it is possible that such experiments do not
detect resistance because the underlying mutations (and com-
binations thereof) are too rare. As a good benchmark, mutation
rate and population size should be high enough to test at least
A
B
Fig. 4. DIvERGE promotes the evolution of antibiotic resistance and simul-
taneously minimizes off-target effects. (A) The fraction of resistant cells
in DIvERGE-mutagenized populations toward rifampicin (representing off-
target) and trimethoprim (targeted by DIvERGE). E. coli K-12 MG1655 served
as a wild-type control. Error bars denote the SEM for 12 biological replicates.
(B) Fitness effect of DIvERGE mutagenesis. Growth rate measurements were
performed on 3 μg/mL (DIvERGE 1) and 50 μg/mL (DIvERGE 2) trimethoprim-
selected, DIvERGE-generated variants (n = 30 for each). The fitness of DIvERGE
1 and 2 are statistically equal to wild-type MG1655 fitness (MG1655 WT) (two-
tailed t test, P = 0.23, and 0.49, respectively).
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three mutations across 99.9% of nucleotide sites in the genome
(6). This would require screening over 1011 wild-type E. coli cells
in a standard fluctuation test (6). Alternatively, with an inoculum
of 107 cells per population, one would have to propagate over
100 E. coli populations for 100 generations (∼40 d) in a serial
passage experiment (6). Clearly, these two main approaches are
tedious and slow. By allowing up to a million-fold increase in
mutation rate at multiple predefined loci, DIvERGE allows deep
scanning of resistance mutations. To reach the benchmark of at
least three mutations across 99.9% of nucleotide sites at up to
four defined loci, DIvERGE merely needs a population of
around 1.4 × 107 E. coli cells, and a single day to perform five
cycles. Therefore, DIvERGE is amenable to predicting resis-
tance mutations in a rapid and parallel manner.
As a proof-of-concept, we demonstrated that DIvERGE iden-
tified several resistance mutations that had previously been de-
tected in trimethoprim- and ciprofloxacin-resistant clinical isolates
(Fig. 6A and Table 2). Within a single screen, DIvERGE not only
detected the major known ciprofloxacin resistance hot-spots but
also discovered resistance-conferring mutations at novel sites.
DIvERGE also revealed major differences in the effects of resis-
tance mutations across bacterial species (Fig. 5C and SI Appendix,
Table S2). This is fully consistent with results of prior papers and
underlines the importance of directly studying the resistance profiles
of the relevant pathogens (61, 62). Finally, we focused on gepoti-
dacin, an antibiotic currently under development. In contrast to
previous claims on the shortage of high-level gepotidacin-resistance
mutations (58), we demonstrated that a combination of two specific
C D
E
F
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Fig. 5. DIvERGE is applicable to multiple hosts and discovers novel antibiotic resistance-conferring mutations. Elevation of mutation frequency, measured as
the frequency of mutations occurring at a given position, after five consecutive DIvERGE cycles shows high locus specificity in (A) S. enterica and (B) C. freundii.
Dashed line indicates cutoff as a qualification of diversified positions, all values below indicate detection limits of the employed sequencing technology (SI
Appendix, SI Materials and Methods) (C) Trimethoprim susceptibility analysis of the strain-specific FolA A7S variant in E. coli K-12 MG1655 and in CFT073
UPEC. Data represent relative inhibitory concentration (AU) compared with the IC75 of the corresponding wild-type strain. Error bars are SDs based on three
independent measurements. (D) DIvERGE revealed distinct mutational hot-spots during adaptation to 267-fold dosage above the wild-type minimum in-
hibitory concentration of trimethoprim in E. coli K-12 MG1655 (marked EC), and S. enterica (marked SE). Figure shows mutation frequency at the detected
mutational hot-spots based on Single Molecule Real-Time (SMRT) sequencing. Promoter (DNA sites below 0) and protein coding regions (amino acid sites
above 0) of folA are indicated. Mutational hot-spots above 0.5% mutation frequency are highlighted in red. (E) Resistance-conferring phenotype of the
DIvERGE identified an E. coli GyrA G288D variant. OD600 indicates the optical density of the bacterial culture after 24 h incubation in the presence of the
corresponding drug concentration. Error bars indicate SD for three parallel measurements. (F) Fitness of the antibiotic-resistant mutant and wild-type E. coli
K-12 MG1655 strains. Using standard procedures (SI Appendix, SI Materials and Methods), fitness was estimated by growth rate in liquid Mueller Hinton II
medium, 24 replicates per genotype. Growth curves were recorded by measuring optical density (OD600) every 7 min for 24 h at 37 °C. GyrA G288D mutant
fitness is significantly lower than wild-type fitness (t test, *P < 4.91 × 10−5). By contrast, GyrA S83L mutant and S83L + D87N double-mutant fitness are
statistically equal to wild-type fitness (t test, P = 0.83, and 0.67, respectively).
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mutations yields an over 500-fold increase in resistance level in
multiple bacterial species. This is all the more relevant, as a stan-
dard frequency of resistance assay failed to identify resistance mu-
tants. Clearly, future studies are needed to determine whether these
mutants are important in the clinical settings.
In the future, DIvERGE could contribute to the identification
of the most promising, less resistance-prone hits from antimicro-
bial compound libraries. We anticipate that recombinases from
other species (63, 64) and novel oligo chemistries (65) will facili-
tate implementation of DIvERGE across a set of host species,
including yeasts and mammalian cells (66–70). DIvERGE may
also be combined with microarray-based DNA synthesis (71), and
thereby randomize up to megabase pairs of target DNA.
Currently, DIvERGE has some important limitations. First, the
genes for targeted mutagenesis have to be defined in advance.
If the loci involved in resistance are unknown, chemogenomics
and related approaches are needed to identify the genes before a
DIvERGE screen (72). Second, subsequent in vivo studies are
needed to demonstrate the viability of the identified mutants in
clinical settings. Third, DIvERGE cannot detect plasmid-mediated
resistance (6, 8). For a broader analysis of horizontally trans-
ferrable resistance processes, protocols of functional metagenomics
(73) and DIvERGE should be integrated in the future. For these
reasons, we anticipate that DNA gyrase and topoisomerase IV
inhibitors are ideal candidates for future DIvERGE studies. Of the
antibiotics currently in clinical development, 24% target these
complexes (74), endogenous mutations are the primary source of
resistance, and the molecular targets of resistance are generally
well-described.
Future Applications
DIvERGE can potentially address several other unmet needs in
basic and applied research. Directed evolution of multiple genes
in their native genomic context is cumbersome with other
methods (14, 18). Improvement of complex traits demands co-
evolution of interacting amino acids that are coded at distinct
loci and many of these mutations provide no benefit individually.
Table 4. Gepotidacin resistance-causing effect of the GyrA
Asp82Asn and ParC Asp79Asn mutation combination in human
pathogenic bacteria
Strain
Gepotidacin
MIC (μg/mL)
MIC (fold-change compared
with the corresponding
wild type)
Escherichia coli O6:K2:H1
CFT073 (UPEC)
>150 >750
Citrobacter freundii
ATCC 8090
>150 >330
Klebsiella pneumoniae
ATCC 10031
125 2,080
The MIC of gepotidacin against wild-type E. coli CFT073, C. freundii ATCC
8090, and K. pneumoniae ATCC 10031, equals 450, 200 and 60 ng/mL, re-
spectively. MIC values were determined according to the EUCAST guidelines.
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Fig. 6. Mutagenesis along the full length of drug-targets discovers resistance-conferring mutations. (A) Map of DIvERGE-identified ciprofloxacin resistance-
conferring mutations at the drug targets of fluoroquinolones in E. coli K-12 MG1655. Figure shows mutation frequencies at detected mutational hot-spots based
on simultaneous Single Molecule Real-Time (SMRT) sequencing at the gyrA, gyrB, parC, and parE loci. Positions are marked with amino acid positions within the
protein-coding region of the target loci. Mutational positions above a 0.5% mutation frequency cut-off are marked in red. (B) Ciprofloxacin resistance-
determining regions of GyrA (red) and GyrB (blue), two subunits of the DNA gyrase complex (PDB ID code 5BS8). The figure also shows the interaction of the
complex with a fluoroquinolone (yellow) and dsDNA (magenta). Mutated positions above the 0.5% mutation frequency cut-offs are indicated and qualified as
mutational hot-spots. (C) Dose–response curves of three DIvERGE-generated gepotidacin resistant E. coli K-12 clones and that of the wild type, parental strain
(Inset). OD600 indicates the optical density of the bacterial culture after 24 h incubation in the presence of the corresponding drug concentration. Measurements
were performed in three replicates according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) guidelines. Error bars indicate SD.
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For these reasons, directed evolution of protein complexes,
multiple enzymatic steps of metabolic pathways, or large cellular
subsystems have remained a formidable problem. DIvERGE
offers a solution as it can explore combinatorial genotypes across
the full lengths of multiple loci. We predict that DIvERGE will
be applicable to optimize metabolic pathways in previously un-
tapped species. For example, C. freundii is an efficient host for
the production of valuable bioproducts (75), but optimization of
metabolic pathways remains challenging in this organism. Other
species, such as Pseudomonas putida, have great potential to
serve as chassis for industrial biotechnology (76) but are thus far
lacking efficient and targeted mutagenesis protocols.
Another potential application is optimization of synthetic DNA
segments. Large de novo constructed DNA elements—from
10 kilobases up-to whole genomes—frequently suffer from sub-
optimal performance due to the unpredictability of their design
guidelines (77). One solution is to design, build, and test mutant
libraries of such constructs (78). DIvERGE can reduce the time-
frame and costs to find an optimal genotype in such engineering
endeavors.
Finally, DIvERGE could be employed to investigate some of the
key issues in evolutionary biology. These issues include the evolu-
tion of mutational effects and epistasis between related species, the
relative contribution of the promoter and protein-coding mutations
to adaptation to novel conditions, and the extent of differences in
the evolutionary routes toward antibiotic resistance in related
pathogens.
Materials and Methods
Please see SI Appendix for the detailed description of materials and methods,
including strains and oligonucleotides, DIvERGE oligonucleotides, DIvERGE
cycling process, determination of mutation frequencies, selection of DIvERGE
libraries, sequencing of folA target regions, nucleotide composition analysis in
Landing Pad libraries and DIvERGE oligo pools, assessment of mutation profiles
in folA libraries with Illumina sequencing, assessment of mutation profiles with
Single Molecule Real-Time sequencing, high-throughput DIvERGE oligo se-
quencing, isolation of individual genotypes, fitness measurements, and anti-
biotic resistance measurements.
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